

| | |
|-------------------------|---|
| 1. Record Nr. | UNINA9910523714603321 |
| Titolo | Clinical applications of SPECT-CT // edited by Hojjat Ahmadzadehfar, Hans-Jurgen Biersack, and Ken Herrmann |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] ©2022 |
| ISBN | 3-030-65850-3 |
| Edizione | [Second edition.] |
| Descrizione fisica | 1 online resource (316 pages) |
| Disciplina | 616.07575 |
| Soggetti | Single-photon emission computed tomography Nuclear medicine |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Nota di bibliografia | Includes bibliographical references and index. |
| Nota di contenuto | Intro -- Contents -- 1: Physics and Technology of SPECT/CT -- 1.1 SPECT/CT: Combining Form with Function -- 1.2 The Development of Multimodality SPECT/CT Imaging -- 1.3 Radiation and Interaction with Matter -- 1.3.1 Photon Attenuation -- 1.4 SPECT Instrumentation -- 1.4.1 Gamma Camera -- 1.4.2 Solid-State Detectors -- 1.5 SPECT Acquisition and Reconstruction -- 1.5.1 Projections and the Radon Transform -- 1.5.2 Image Reconstruction: Filtered Back-Projection (FBP) -- 1.5.3 Image Reconstruction: Iterative Techniques. -- 1.5.4 Corrections for Photon Attenuation and Scattering -- 1.5.5 Corrections for Resolution -- 1.6 CT for SPECT/CT -- 1.7 Quantitative SPECT/CT -- 1.8 Radiation Dose from SPECT/CT -- 1.9 QC for SPECT/CT -- 1.10 Combined SPECT and CT -- References -- 2: SPECT Radiomics: The Current Landscape, Challenges, and Opportunities -- 2.1 Introduction -- 2.2 Radiomics as a Methodology -- 2.3 Clinical Application of Radiomics Using SPECT -- 2.3.1 Oncologic SPECT Radiomics -- 2.3.2 Neurologic SPECT Radiomics -- 2.3.3 Cardiac SPECT Radiomics -- 2.3.4 Other Applications of SPECT Radiomics -- 2.4 Challenges and Opportunities of SPECT Radiomics -- References -- 3: SPECT/CT for Dosimetry -- 3.1 Introduction -- 3.2 SPECT Versus Planar -- 3.3 SPECT/CT Versus SPECT -- 3.4 Choice of a Surrogate -- 3.5 SPECT/CT-Based Dosimetry Studies -- 3.5.1 Yttrium-90 Spheres Dose-Response -- 3.5.2 Yttrium-90 Spheres |

Dose-Toxicity -- 3.5.3 Yttrium-90 PRRT -- 3.5.4 Holmium-166 -- 3.5.5 Lutetium-177 Antibody -- 3.5.6 Lutetium-177 PRRT -- 3.5.7 Iodine-131 -- 3.5.8 Alpha Emitters -- 3.5.9 SPECT/CT-Based Individualized Therapy Planning -- 3.5.10 Perspectives: Compton Cameras -- 3.6 Conclusions -- References -- 4: SPECT/CT Imaging in Hyperparathyroidism and Benign Thyroid Disorders -- 4.1 Hyperparathyroidism -- 4.1.1 Embryology. 4.1.2 Pathophysiology, Treatment Goals, and Strategies -- 4.1.2.1 Primary Hyperparathyroidism -- 4.1.2.2 Secondary Hyperparathyroidism -- 4.1.2.3 Tertiary Hyperparathyroidism -- 4.1.3 Role of Parathyroid Scintigraphy -- 4.1.3.1 Primary Hyperparathyroidism -- Initial Surgery for pHPT -- Persistent or Recurrent HPT -- 4.1.3.2 Renal Hyperparathyroidism -- Initial Surgery for rHPT -- Persistent or Recurrent rHPT -- 4.1.4 Planar Parathyroid Scintigraphy -- 4.1.5 Dual-Phase Protocol -- 4.1.6 Subtraction Protocol -- 4.1.7 Sensitivity and Specificity -- 4.1.8 SPECT/CT -- 4.1.8.1 Primary Hyperparathyroidism -- 4.1.8.2 Renal Hyperparathyroidism -- 4.1.9 Conclusion Remarks -- 4.2 Benign Thyroid Disorders -- 4.2.1 Ectopic Thyroid Tissue -- 4.2.2 Intrathoracic Goitre -- 4.2.3 Ovarian Teratoma -- References -- 5: SPECT/CT for Thyroid Cancer Imaging -- 5.1 Introduction -- 5.2 Radioiodine SPECT/CT -- 5.3 Early Use of Radioiodine SPECT/CT -- 5.4 Utility of Post-therapy Radioiodine SPECT/CT -- 5.5 Utility of Diagnostic and Pre-ablation Radioiodine SPECT/CT -- 5.6 SPECT/CT Evaluation of Unusual Radioactive Distributions -- 5.7 Changes to Clinical Management -- 5.8 Comparison to Other Imaging Modalities -- 5.9 Utility of Radioiodine SPECT/CT for Lesional Dosimetry -- 5.10 Disadvantages and Limitations of SPECT/CT -- 5.11 Conclusion -- References -- 6: SPECT/CT in Neuroendocrine Tumours -- 6.1 Introduction -- 6.2 Epidemiology -- 6.3 Physiology -- 6.4 Somatostatin -- 6.4.1 Somatostatin Receptors -- 6.5 Classification -- 6.6 Diagnostical Tracers (Somatostatin Receptor-Based Imaging) -- 6.6.1 [111In]-DTPA-D-Phe1-Octreotide -- 6.6.2 [99mTc]-EDDA/HYNIC-Tyr3-Octreotide ([99mTc]-TEKTROTYD®) -- 6.6.3 [99mTc]-Depreotide (NeoSPECT®) -- 6.6.4 [123I]-MIBG -- 6.6.5 Other Radiolabelled Peptide Receptor Tracers. 6.7 Therapy of Neuroendocrine Neoplasms -- 6.7.1 Peptide Receptor-Based Radionuclide Therapy (PRRT/PRRNT) -- 6.7.2 [177Lu]-DOTA0-Tyr3-Octreotate -- 6.7.3 Dosimetry -- 6.7.4 [90Y]-DOTA0-Tyr3-Octreotide -- 6.7.5 [90Y]-Microspheres and [166Ho]-Microspheres -- 6.7.6 [131I]-MIBG -- 6.8 Summary -- References -- 7: 123I/131I-MIBG SPECT/CT for Tumour Imaging -- 7.1 Introduction -- 7.2 Physical Properties of 123I and 131I -- 7.3 Indications for mIBG Scan -- 7.4 Patient Preparation -- 7.5 Interfering Drugs -- 7.6 Contraindications -- 7.7 Dose Calculation -- 7.8 Image Acquisition -- 7.9 Acquisition of SPECT/CT -- 7.10 Reconstruction of SPECT/CT -- 7.11 Radiation Exposure -- 7.12 Physiological mIBG Uptake and Distribution -- 7.13 The Importance of mIBG SPECT and SPECT/CT -- 7.14 MIBG SPECT/CT in Neuroblastoma -- 7.14.1 Interpretation of the Findings: What Is Physiological? -- 7.14.2 Image Interpretation -- 7.14.2.1 False-Negative Findings -- 7.14.2.2 False-Positive Findings -- 7.14.3 SPECT/CT: Reducing False-Negative and -Positive Results -- 7.15 MIBG SPECT/CT in Pheochromocytoma and Paraganglioma -- 7.15.1 Interpretation of the Findings -- 7.16 mIBG SPECT/CT in Medullary Thyroid Carcinoma -- 7.16.1 Imaging Procedures -- References -- 8: Bone SPECT/CT in Oncology -- 8.1 Introduction -- 8.2 Radiopharmaceutical for Bone Scintigraphy/SPECT-CT -- 8.3 Radiopharmaceutical Activity -- 8.4 Bone SPECT/CT Patient

Preparation -- 8.5 Image Acquisition Protocol -- 8.6 Role of SPECT-CT in Bone Metastases -- 8.7 Radiological Imaging -- 8.8 Bone Scintigraphy -- 8.9 Bone SPECT-CT -- 8.10 Artifacts on SPECT/CT -- 8.11 Literature Evidence on the Role of Bone SPECT/CT in Metastases -- 8.11.1 Primary Bone Malignancy -- References -- 9: Bone SPECT/CT in Orthopaedics -- 9.1 Introduction -- 9.1.1 Indications -- 9.1.2 Radiopharmaceuticals. 9.1.3 Radiopharmaceutical Activity -- 9.2 Bone SPECT/CT: Patient Preparation -- 9.3 Image Acquisition Protocol -- 9.4 Bone SPECT/CT in Different Benign Bone Conditions -- 9.4.1 Enchondroma -- 9.4.2 Shin Splint -- 9.4.2.1 SPECT-CT Findings -- 9.4.3 Avascular Necrosis -- 9.4.3.1 SPECT-CT Findings -- 9.4.4 Sacroiliitis -- 9.4.4.1 SPECT-CT Findings -- 9.4.5 Paget's Disease -- 9.4.5.1 SPECT-CT Findings -- 9.4.6 Fibrous Dysplasia -- 9.4.6.1 SPECT-CT Findings -- 9.4.7 Hypertrophic Pulmonary Osteoarthropathy -- 9.4.7.1 SPECT-CT Findings -- 9.4.8 Trauma -- 9.4.8.1 SPECT-CT Findings -- 9.4.9 Identification of Pain Generator (Prosthesis Related) -- 9.4.9.1 SPECT-CT Findings -- 9.4.10 Complex Regional Pain Syndrome -- 9.4.10.1 SPECT-CT Findings -- 9.4.11 Bone Infarct -- 9.4.11.1 SPECT-CT Findings -- 9.4.12 Heterotopic Ossification -- 9.4.12.1 SPECT-CT Findings -- 9.4.13 Condylar Hyperplasia -- 9.4.13.1 SPECT-CT Findings -- 9.4.14 Graft Viability Evaluation -- 9.4.14.1 SPECT-CT Findings -- 9.4.15 Vertebral Compression Fracture -- 9.4.15.1 SPECT-CT Findings -- 9.4.16 Spondylodiscitis -- 9.4.16.1 SPECT-CT Findings -- 9.4.17 Intraosseous Disc Herniation -- 9.4.17.1 SPECT-CT Findings -- 9.4.18 Osteomyelitis -- 9.4.18.1 SPECT-CT Findings -- References -- 10: SPECT/CT for Imaging of Coronary Artery Disease -- 10.1 Introduction -- 10.2 Myocardial Perfusion Imaging -- 10.3 Cardiac CT -- 10.3.1 Coronary Artery Calcium CT -- 10.3.2 Coronary Computed Tomographic Angiography -- 10.4 Integration of Nuclear MPI and CT -- 10.4.1 Integration of CT with MPI for Attenuation Correction -- 10.4.2 MPI and CAC -- 10.4.3 MPI and CCTA -- 10.5 Radiation Exposure -- 10.6 Clinical Applications -- 10.7 Future Perspective of Cardiac SPECT/CT -- References -- 11: SPECT/CT in Sentinel Node Scintigraphy -- 11.1 Introduction -- 11.2 Clinical Background. 11.3 Technical SPECT-CT Aspects for SN Imaging -- 11.4 Comprehensive Interpretation of Lymphoscintigraphy and SPECT/CT -- 11.5 Clinical Relevance of SPECT/CT -- 11.5.1 Cutaneous Melanoma -- 11.5.2 Breast Cancer -- 11.5.3 Head and Neck Malignancies -- 11.5.4 Pelvic and Retroperitoneal Malignancies -- 11.5.5 Other Malignancies -- 11.6 General Indications of SPECT/CT -- 11.7 SPECT/CT as a Roadmap for Intraoperative Detection of Sentinel Nodes -- 11.8 New Strategies Combining SPECT/CT and PET/CT -- References -- 12: Lung SPECT/CT -- 12.1 Introduction -- 12.2 Limitations of Planar Lung Scintigraphy -- 12.3 Advantages of SPECT Imaging -- 12.4 Need for Correlation with Anatomical Imaging -- 12.5 Combining Functional and Anatomical Images -- 12.5.1 Visual and Software Fusion -- 12.5.2 Hardware Fusion -- 12.6 V/Q Lung SPECT/CT -- 12.6.1 SPECT and CTPA Fusion -- 12.6.2 Combined V/Q SPECT with Low-Dose CT -- 12.6.2.1 Overview -- 12.6.2.2 Protocols -- Ventilation -- Perfusion -- SPECT: Gamma Camera Hardware, Image Acquisition and Processing -- CT Protocols for Use with SPECT V/Q Scans -- Image Display and Reviewing -- 12.7 Clinical Value of V/Q SPECT/CT -- 12.8 Is the Ventilation Scan Necessary? -- 12.9 How Does V/Q SPECT/CT Compare with CTPA? -- 12.10 Clot Localisation -- 12.11 Consolidative Opacities -- 12.12 Barriers to Implementation of V/Q SPECT/CT -- 12.13 Thrombus Imaging -- 12.14 V/Q SPECT/CT: Role in Applications Other than PE -- 12.14.1 Radiotherapy

Treatment Planning -- 12.14.2 Lung Reduction Surgery Planning --
12.15 Further Uses -- 12.16 Quantitative V/Q SPECT -- 12.17
Conclusion -- References -- 13: Therapy Planning with SPECT/CT
in Radioembolization of Liver Tumours -- 13.1 Introduction -- 13.2
The Significance of ^{99m}Tc -MAA SPECT/CT Liver Perfusion Imaging
in the Treatment Planning of RE -- 13.3 Image Acquisition.
13.4 ^{99m}Tc -MAA SPECT/CT in the Evaluation of Extrahepatic
Deposition of Tracer.
